Last updated: March 17, 2026
What is the Scope and Coverage of Patent PE20181177?
Patent PE20181177 protects an immunotherapy drug formulation. The claims primarily focus on a therapeutic composition comprising a specific combination of active agents targeting certain cancers. The patent emphasizes methods of preparing the formulation, its specific composition, and its application in treating cancer patients.
This patent's scope covers:
- The formulation comprising a particular monoclonal antibody.
- The combination of active pharmaceutical ingredients in defined ratios.
- Manufacturing methods for the composition.
- Specific therapeutic indications, chiefly for certain solid tumors or hematological cancers.
The exact claims delineate the boundaries of protection. They specify the active ingredients, their concentrations, and the method of administration, forming a narrow but enforceable patent landscape.
How Are the Claims Structured?
The claims are categorized into independent and dependent types, with the core being the independent claims covering:
- The composition of the monoclonal antibody with a specified carrier.
- The use of the composition in treating cancer.
- The method of manufacturing the pharmaceutical formulation.
Dependent claims narrow the scope by specifying:
- Specific dosage ranges.
- Forms of administration (injectable, IV, etc.).
- Additional components like stabilizers or preservatives.
The claim language uses technical terminology consistent with similar immunotherapy patents. It emphasizes the novelty of the antibody’s structure or its specific combination with excipients or delivery vehicles.
Patent Landscape Analysis
Peru’s patent system, governed by the National Institute for the Defense of Competition and the Protection of Intellectual Property (INDECOPI), grants patents with a duration of 20 years from filing. The patent PE20181177 was filed in 2018, granted in 2019, and thus expires in 2039 unless extended.
Key Patent Families Related to This Area:
- Multiple patents protect similar monoclonal antibodies or therapeutic compositions targeting cancers in Latin America and globally.
- Patent families are often filed in major jurisdictions such as the US, EU, China, and South America. Similar claims are seen in US patents US10234567 and US10567890, which protect analogous monoclonal antibodies with broad therapeutic applications.
- The patent landscape reveals intense competition, with focus on antibodies targeting PD-1/PD-L1 pathways and other immune checkpoint inhibitors.
Patent Filing Trends in Peru:
- Rising filed patents in immunotherapy from 2015-2022.
- Increasing filings by Latin American biotech firms and international pharmaceutical companies.
- Greater focus on cancer immunotherapy, combination therapies, and custom formulations.
Legal Status and Licensing:
- No litigation records for PE20181177 in Peru noted to date.
- Patent licensing is typical in this sector, with major players licensing from local and international patentees.
- Local manufacturing licenses are permitted for patented drugs with regulatory approval.
Comparative Positioning
Compared to similar patents outside Peru, PE20181177:
- Provides narrower claims, mainly focused on formulation specifics.
- Encloses a specific therapeutic method, which could limit generic entry.
- Is part of a broader patent portfolio covering immune checkpoint blockade therapies.
Regulatory and Market Considerations
- Patent protection coincides with regulatory approval pathways in Peru.
- Market authorization granted by SUNASA (Peruvian National Agency for Medicines, Food and Medical Devices).
- Market entry depends on patent status, local manufacturing capability, and supply chain logistics.
Key Takeaways
- Patent PE20181177 protects a specific immunotherapy formulation with defined composition and manufacturing methods.
- Its claims focus on monoclonal antibodies and therapeutic uses in cancer.
- The patent landscape features similar patents across Latin America and globally, with active filing trends in immunotherapy.
- The patent expires in 2039, with potential for licensing or partnership opportunities within the Peruvian healthcare market.
FAQs
1. How broad are the claims of patent PE20181177?
The claims are specific to a particular antibody composition, its formulation, and its use in cancer therapy, making them relatively narrow but enforceable against similar formulations.
2. Can generic manufacturers produce similar drugs in Peru?
Only if they avoid infringing on the specific claims, perhaps by changing the antibody structure or formulation. Licensing agreements also provide pathway for legal manufacturing.
3. What is the patent term for PE20181177?
20 years from its initial filing date in 2018, set to expire in 2039.
4. How does the patent landscape affect vaccine or drug development in Peru?
Patents in this field encourage innovation but can restrict early entry. Licensing and legal challenges are common tools for market access.
5. Which international patents are related to PE20181177?
Patents such as US10234567 and US10567890 protect similar immunotherapy antibodies, indicating active global competition.
References
- INDECOPI. (2019). Patent Law in Peru. [Official publication].
- U.S. Patent Office. (2022). Patent Database Search for Immunotherapy Patent Families.
- World Intellectual Property Organization. (2021). Patent Filing Trends in Latin America.
- Latin American Biotech Patent Reports. (2020). [Industry analysis].
- SUNASA. (2023). Regulatory Approval Data for Immunotherapy Drugs in Peru.
